12:00 AM
 | 
Jul 02, 2012
 |  BC Week In Review  |  Company News  |  Deals

Angiogene Pharmaceuticals, OxiGene deal

Angiogene granted OxiGene exclusive, worldwide rights to IP, patents and preclinical data related to Angiogene's vascular disrupting agent to treat carcinoid syndrome. OxiGene plans to use the IP to develop its Zybrestat fosbretabulin to treat carcinoid syndrome associated with metastatic carcinoid...

Read the full 193 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >